ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a long-acting PEGylated form of recombinant human Interleukin-10 (IL-10), have been accepted for poster presentation at the upcoming 2018 ASCO Annual Meeting, taking place June 1-5, 2018 at McCormick Place, in Chicago, Illinois.
Title: Overall Survival of PEGylated Pegilodecakin with 5-FU/LV and Oxaliplatin (FOLFOX) in Metastatic Pancreatic Adenocarcinoma (PDAC).
Title: Responses and Durability in NSCLC Treated with Pegilodecakin and anti-PD-1
Title: Pegilodecakin with Nivolumab (nivo) or pembrolizumab (pembro) in Patients with Metastatic Renal Cell Carcinoma (RCC)
Additional details on the ASCO poster presentations will be announced on May 16, 2018 at 5:00 pm Eastern Time.